

**Julie A. Kreyenbuhl, Pharm.D., Ph.D.**

VA Capitol Healthcare Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC) and  
University of Maryland School of Medicine, University of Maryland Department of Psychiatry,  
Division of Services Research  
Baltimore VAMC  
10 N. Greene St. (BT/MIRECC)  
Baltimore, MD 21201  
E-mail: Julie.Kreyenbuhl@va.gov  
Phone: 410-637-1864 FAX: 410-637-1880

**Education**

1987-1989 Mercer University, Macon, GA  
1989-1993 Mercer University Southern School of Pharmacy, Atlanta, GA (Pharm.D., Magna cum laude)  
1993-1999 University of Maryland, Baltimore, MD (Ph.D., Pharmaceutical Health Services Research)

**Post Graduate Education and Training**

1999-2000 Post-Doctoral Fellowship  
Maryland Psychiatric Research Center, Treatment Research Unit,  
University of Maryland School of Medicine  
Mentors: Raymond C. Love, Pharm.D., Robert R. Conley, M.D.  
2003-2005 Graduate Coursework in Cognitive Psychology, Judgment and Decision-Making, Survey Sampling, and Multilevel Analysis of Survey Data  
University of Maryland, College Park

**Professional Experience**

1993-1999 Doctoral Student, Department of Pharmacy Practice and Science, School of Pharmacy, University of Maryland, Baltimore, MD.  
Dissertation: Correlates of Psychopharmacologic Treatment Outcomes for Schizophrenia (Advisor: Julie M. Zito, Ph.D.)  
1993-1994 Teaching Assistant, Department of Pharmacy Practice and Science, School of Pharmacy, University of Maryland, Baltimore, MD.  
1994 - 1999 Policy Fellow, Center on Drugs and Public Policy, Department of Pharmacy Practice and Science, School of Pharmacy, University of Maryland, Baltimore, MD.

1996-1997	<u>Research Assistant</u> , Center for Mental Health Services Research, Department of Psychiatry, School of Medicine, University of Maryland, Baltimore, MD.
1999-2000	<u>Post-Doctoral Fellow</u> , Maryland Psychiatric Research Center, Treatment Research Unit, Department of Psychiatry, School of Medicine, University of Maryland, Baltimore, MD.
2000-2009	<u>Assistant Professor of Psychiatry</u> , Division of Services Research, School of Medicine, University of Maryland, Baltimore, MD.
2009-present	<u>Associate Professor of Psychiatry</u> , Division of Services Research, School of Medicine, University of Maryland, Baltimore, MD.
2000-present	<u>Investigator</u> , VA Capitol Healthcare Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC), Veterans Administration Maryland Healthcare System, Baltimore, MD.
2009-present	<u>Assistant Director</u> , Research Core, VA Capitol Healthcare Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC), Veterans Administration Maryland Healthcare System, Baltimore, MD.

### **Honors and Awards**

1987-1989	Mercer University Penfield Scholarship
1989-1990	Mercer University Southern School of Pharmacy First Year Merit Scholarship
1991-1993	GPhA Greater Atlanta Women's Auxiliary Scholarship
1991	Who's Who Among Students in American Colleges and Universities
1991	Rho Chi Society
1991	Parke-Davis Summer Internship Program
1992	Kappa Epsilon Zada M. Cooper Scholarship
1992	National Pharmaceutical Council Summer Internship Program (Procter and Gamble Pharmaceuticals)
1992	NationsBank Scholarship
1992	McNeil Consumer Products Company Award
1993	The Honor Society of Phi Kappa Phi
1993	Annie Grace Reynolds Sillin Award for Business Achievement
1993-1994	American Foundation for Pharmaceutical Education (AFPE)/Glaxo First Year Graduate Studies Scholarship
1994-1995	Balfour Fellowship
1994-1996	Procter & Gamble Fund-AFPE Pharmacoeconomics Fellowship
1996	Best Poster Presentation (Pharmaceutical Sciences Section) - Graduate Student Research Day, University of Maryland
2000	New Clinical Drug Evaluation Unit (NCDEU) New Investigator Award
2003	H. McKee Jarboe Award for Mental Health Research, University of Maryland
2008	Outstanding Reviewer Recognition, <i>Pharmacoepidemiology and Drug Safety</i>

## **Administrative Service**

### **Institutional Service**

- 2002-present Co-chairperson, Department of Psychiatry Research Day, University of Maryland School of Medicine
- 2002-2009 Lecturer in Research Methods for Psychiatry Residents, Department of Psychiatry, University of Maryland School of Medicine
- 2002-present MIRECC representative, Performance Improvement Sub-Council, Mental Health Service Line, VA Maryland Health Care System, VISN 5
- 2003-present Member, Institutional Review Board, University of Maryland School of Medicine
- 2003-present Coordinator, Medical Student Research Experience Program, Division of Services Research, Department of Psychiatry, University of Maryland School of Medicine
- 2003-present Member, Clozapine Treatment Team, Mental Health Service Line, VA Maryland Health Care System
- 2003 MIRECC representative, Seriously Chronically Mentally Ill Sub-Committee, Mental Health Service Line, VA VISN 5
- 2004-2005 Coordinator, Research Methods for Psychiatry Residents, Department of Psychiatry, University of Maryland School of Medicine
- 2005-present Member, Data and Safety Monitoring Board, Maryland Psychiatric Research Center, University of Maryland School of Medicine
- 2006-present Co-leader, Monthly Psychopharmacology Case Conference, Mental Health Service Line, VA Maryland Health Care System
- 2008-2010 Interviewer of medical school applicants, University of Maryland School of Medicine
- 2010-2012 Member, Grant Review Subcommittee, VA Maryland Health Care System Research and Development Committee
- 2012 Member, Conference Planning Committee, “*Supporting the Mental Health of Women Veterans*”, VA VISN 5 MIRECC

### **National Service**

- 2002 Ad Hoc Grant Reviewer, Canadian Institutes of Health Research
- 2002-present Ad Hoc Journal Reviewer: *Academic Psychiatry, Acta Psychiatrica Scandinavica, American Journal of Geriatric Psychiatry, American Journal of Preventive Medicine, American Journal of Psychiatry, Expert Review of Neurotherapeutics, Harvard Review of Psychiatry, Journal of Clinical Psychiatry, Journal of Nervous and Mental Disease, Medical Care, Pharmacoepidemiology and Drug Safety, Psychiatric Services, Schizophrenia Bulletin, Schizophrenia Research*
- 2003 Consultant, American Psychiatric Association, assisted in writing and editing of *Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition, 2004*
- 2005 Consultant, American Psychiatric Institute for Research and Education, assisted on a project (*Quality Measures for Schizophrenia Treatment Guidelines*) that identified evidence-based quality indicators for schizophrenia treatments

- 2005 Self-Care Subcommittee, VHA My HealthVet Mental Health Portal Working Group
- 2006-2008 Member, Data and Safety Monitoring Board, *A Double-Blind Trial of Allopurinol to Reduce the Symptoms of Schizophrenia*, Faith B. Dickerson, Ph.D. (Principal Investigator), Sheppard Pratt Health System
- 2007 Ad hoc member, Cooperative Studies Scientific Merit Review Board, VA Clinical Science Research and Development Service
- 2007 Ad Hoc Grant Reviewer, ZonMw (Netherlands)
- 2008-2010 Chair, Data and Safety Monitoring Board, *Double-blind Trial of Artemisinin to Reduce the Symptoms of Schizophrenia*, Faith B. Dickerson, Ph.D. (Principal Investigator), Sheppard Pratt Health System, Baltimore, Maryland
- 2011-2012 Chair, Data and Safety Monitoring Board, *A Double-Blind Placebo-Controlled Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia*, Faith B. Dickerson, Ph.D. (Principal Investigator), Sheppard Pratt Health System, Baltimore, Maryland
- 2011-present Member, Data and Safety Monitoring Board, *Peer Mentors to Improve Smoking Cessation in Persons with Serious Mental Illness*, Faith B. Dickerson, Ph.D. (Principal Investigator), Sheppard Pratt Health System
- 2012-present Member, VA Mental Health Quality Enhancement Research Initiative (QUERI) SMI Health Workgroup
- 2012-present Ad-hoc member, HSR-4 (Mental and Behavioral Health) Scientific Merit Review Board (SMRB), VA Health Services Research and Development Service
- 3/2012 Ad-hoc member, HCR-1 (CREATE-PTSD) Scientific Merit Review Board (SMRB), VA Health Services Research and Development Service
- 3/2012 Ad-hoc member, HCR-2 (CREATE-Substance Use Disorders) Scientific Merit Review Board (SMRB), VA Health Services Research and Development Service
- 2012-present Member, VA Reproductive Mental Health Steering Committee, Women Veterans Health Strategic Healthcare Group (WVHSHG)
- 2012-present Member, Data and Safety Monitoring Board, *A Double-Blind Placebo-Controlled Trial of a Probiotic Supplement to Prevent Relapse and Improve the Clinical Course After Hospitalization for Mania*, Faith B. Dickerson, Ph.D. (Principal Investigator), Sheppard Pratt Health System

### **Professional Society Memberships**

- 1989 - 1999 American Pharmaceutical Association (APhA)  
Academy of Pharmaceutical Research and Science (APRS) Graduate Students Working Group (1994)  
APRS Delegate to the APhA House of Delegates, Seattle, WA (1994)
- 1990 - 1991 Georgia Pharmaceutical Association (GPhA)  
Standing Committee on Public Relations (1990-1991)
- 1990 - present Kappa Epsilon Professional Pharmacy Fraternity  
Bond Reporter (1993-1995)  
Chairperson, National Scholarship Committee (1994-present)
- 1990-1994 American Society of Hospital Pharmacists/Georgia Society of Hospital Pharmacists
- 1994-1998 American Association of Colleges of Pharmacy
- 1995-1997 Association for Pharmacoeconomics and Outcomes Research

1995-present AcademyHealth  
1996-present American Public Health Association  
2002-2006 Society for Medical Decision Making

## **Grant Support**

### **Completed Grants**

Center on Services for Severe Mental Illness

PI: Donald Steinwachs, Ph.D., Co-PI: Anthony F. Lehman, M.D., M.S.P.H.

National Institute of Mental Health (P50 MH43703)

9/1/00-7/21/05 (\$1,070,756)

Role: Co-Investigator

The aims for this Center were to conduct research on financing for and outcomes of treatments and services for adults with serious mental illnesses.

Prescription of Multi-Drug Psychopharmacologic Treatments in Schizophrenia

PI: Julie Kreyenbuhl, Pharm.D., Ph.D.

University of Maryland School of Medicine Intramural New Investigator Grant

7/1/02-6/30/03 (\$15,000)

The goal of this project is to describe the extent of the prescription of multi-drug regimens, and to model its relationship to selected outcomes (e.g., symptom reduction, adverse effects, mental health services use) among persons with schizophrenia in two mental health service settings. The models will be applied to a larger population of veterans with schizophrenia in order to estimate the clinical and non-clinical consequences of the prescription of multi-drug regimens.

Do Practice Guidelines Reduce Smoking in Schizophrenia?

PI: Lisa B. Dixon, M.D., M.P.H.

National Institute on Drug Abuse (R01 DA014393)

4/1/02-3/31/05 (\$1,658,042)

Role: Co-Investigator

This study tested the impact of implementing the Agency for Healthcare Research and Quality (AHRQ) smoking cessation guidelines on brief physician-delivered smoking cessation interventions among people with schizophrenia.

Does a CTI Improve Psychiatric Inpatient-Outpatient Transition Outcomes?

PI: Lisa B. Dixon, M.D., M.P.H.

VA Health Services Research & Development Service (VCR-02-166)

10/01/02-9/30/05 (\$600,000)

Role: Co-Investigator

This study utilized an experimental random-assignment design to test a brief 3-month, relatively low intensity critical time intervention (CTI) for veterans with serious mental illnesses at the point of inpatient-outpatient transition. The CTI model is intended to enhance the continuity of mental

health services for mentally ill individuals at the time of this transition by helping them bridge the gap between institutional and community based services.

#### Understanding Prescription Decisions in Schizophrenia

PI: Julie Kreyenbuhl, Pharm.D., Ph.D.

National Institute of Mental Health Research Career Award (K01 MH066009)

4/01/03-11/10/09 (\$652,822)

This application proposes a 5-year integrated training and research program to investigate the process of clinical decision-making as it relates to the prescription of complex, multi-drug regimens ('polypharmacy') for schizophrenia. Both clinician-related and patient and family-related factors, which are equally important and influential forces affecting medication management decisions will be considered.

#### National Center on Minority Health and Health Disparities

PI: Donald Wilson, M.D.

National Institutes of Health (P60 MD00532)

10/01/03-9/30/07 (\$399,999)

Role: Co-Investigator, Mental Health Core

The aims for the Center were to foster health disparities research on renal and eye disease, cancer and mental health.

#### Medical Co-Morbidity in Schizophrenia: A Focus on Diabetes—Four Year Follow Up

PI: Lisa B. Dixon, M.D., M.P.H.

Bristol-Myers Squibb Company

2/1/05-1/31/07 (\$464,576)

Role: Co-Investigator

This investigation involved a four year follow-up study of 300 people who participated in an earlier study of diabetes, Morbidity in Schizophrenia: A Focus on Diabetes (RO1 MH58717). The goals of this prospective, longitudinal study were: (1) Among persons with severe mental illnesses prescribed antipsychotic medications, to evaluate the relationship between the antipsychotic medication prescribed and diabetes outcomes, weight gain, and diabetes complications over the four-year follow-up period; and (2) to characterize the changes over four years in diabetes outcomes and complications, quality of diabetes care, and general health status among persons with diabetes, and to determine if persons with schizophrenia differ from persons with major affective disorders or persons without SMI.

#### Adherence to Medications for Type 2 Diabetes Among Patients with Schizophrenia

PI: Julie Kreyenbuhl, Pharm.D., Ph.D.

NARSAD Young Investigator Award

7/1/05-6/30/08 (\$60,000)

Two complementary studies using different patient populations and methods of assessing medication adherence will be conducted to investigate whether patients with schizophrenia and Type 2 diabetes exhibit differential rates of adherence to hypoglycemic medications versus antipsychotic medications. We will also investigate whether patients with schizophrenia exhibit differential rates of adherence to medications for Type 2 diabetes

compared to patients without a psychiatric disorder. The first study will use administrative encounter data from two large VA registries to measure medication adherence using pharmacy refill data for a nationwide sample of veterans. The second study will assess medication adherence by patient self-report and the Medication Management Ability Assessment, a performance-based measure of general medication adherence involving a brief role-play task.

#### Adherence to Medications for Type 2 Diabetes Among Patients with Schizophrenia

PI: Julie Kreyenbuhl, Pharm.D., Ph.D.

VA Capitol Healthcare Network (VISN 5) Mental Illness, Research, Education and Clinical Center Research Core Pilot Project Funding

7/1/05-6/30/06 (\$15,000)

This grant provides supplemental funding for veteran participants in the second NARSAD study described above that evaluates self-reported adherence to oral hypoglycemic medications in diabetes patients with and without co-occurring schizophrenia.

#### Schizophrenia PORT Treatment Recommendations Update 2008

PI: Julie Kreyenbuhl, Pharm.D., Ph.D.

National Institute of Mental Health (R13 MH080593)

4/05/07-3/31/09 (\$167,270)

The Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations were developed to help ensure that individuals with schizophrenia receive the highest quality treatments supported by current empirical knowledge. This R13 Conference Grant provides funding to organize and direct a conference in 2008 to develop expert consensus on the evidence base to update and expand the Schizophrenia PORT Treatment Recommendations. This grant will enable the development of an infrastructure to review new research findings published since 2002 on the efficacy and effectiveness of treatments for schizophrenia that will be discussed at the conference.

#### Schizophrenia PORT Treatment Recommendations Update 2008 – VA Supplement

PI: Julie Kreyenbuhl, Pharm.D., Ph.D.

Veterans Health Administration

4/05/07-3/31/09 (\$100,000)

The VA is dedicated to supporting the development of treatment guidelines and disseminating evidence-based practices throughout their healthcare system, especially in the area of mental health. This grant provides supplemental financial support and endorsement by the Veteran's Affairs (VA) health system to the 2008 update of the Schizophrenia PORT treatment recommendations. PORT investigators will interact with key VA mental health staff to discuss strategies for dissemination of the recommendations within the VA healthcare system.

#### Implementing Web-Based Patient Education Materials for Veterans with Serious Mental Illnesses

PI: Julie Kreyenbuhl, Pharm.D., Ph.D.; Co-PI: Alex Young, M.D., M.P.H.

Veterans Health Administration

08/01/08-07/31/09

This grant provides funding for a joint project between the VISN 5 and VISN 22 MIRECCs to develop an internet-based education program focused on improving medical wellness in veterans with serious mental illnesses (SMI).

Heterogeneity and Econometric Net Cost Estimates of Schizophrenia Drug Treatments

P.I.: David Salkever, Ph.D.

National Institute of Mental Health (R03 MH083208)

4/1/08-3/31/10 (\$148,000)

Role: Consultant

This three-year study will provide a comprehensive description of mental health services utilization among young adults with mental health problems in the Medicaid program, including their access to care and patterns of mental health treatment in the specialty mental health, acute care, and primary care sectors.

Use of Mental Health and Primary Care Services Among Disadvantaged Young Adults

PI: Eric Slade, Ph.D.

National Institute of Mental Health (R34MH081303-01)

8/1/07-7/31/10 (\$450,000)

Role: Co-Investigator

This three-year study will provide a comprehensive description of mental health services utilization among young adults with mental health problems in the Medicaid program, including their access to care and patterns of mental health treatment in the specialty mental health, acute care, and primary care sectors. The study will focus on understanding the particular roles of Medicaid insurance continuity (i.e. periods without lapses in coverage) and access to primary care services in enabling continued mental health treatment.

Determinants of Diabetes Control in Veterans with Serious Mental Illness

PI: Judith A. Long, MD

VA Health Services Research and Development Service (IIR 07-124-3)

7/1/09-1/31/12 (\$653,000)

Role: Co-Investigator

This study involves a quantitative cross-sectional survey of 400 veterans with serious mental illness and Type 2 diabetes to evaluate whether glucose control and adherence to diabetes medications differs according to whether diabetes care is delivered in usual primary care settings vs. in settings where primary care is collocated within a mental health clinic.

## **Active Grants**

HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users

PI: Seth Himelhoch, M.D., M.P.H.

National Institute of Drug Abuse (R34 DA03241)

9/15/2011-9/15/2014 (\$450,000)

Role: Co-Investigator

The goal of this research is to develop and pilot test a Smartphone-based intervention called *HEART (Helping Enhance Adherence to Retroviral therapy using Technology) to HAART*, to enhance adherence to HAART among HIV infected drug users.

A Smartphone Intervention to Improve Adherence to Antipsychotic Medications

PI: Julie Kreyenbuhl, Pharm.D., Ph.D.

National Institute of Mental Health (R34 MH094555)

8/15/2011–7/31/2014 (\$453,755)

The goal of this grant is to evaluate the feasibility and acceptability of a mobile smartphone intervention, *MedActive*, on improving antipsychotic adherence among individuals with schizophrenia. *MedActive* is an ecological momentary intervention that provides medication reminders and queries individuals about their intentions to take the medication while also collecting real-time psychiatric symptom and side effect data that can be displayed for individuals and their clinicians. Iterative versions of *MedActive* will be tested in a short-term field trial and a randomized pilot study involving individuals with schizophrenia and their psychiatrists.

Web-Based Delivery of *MOVE!* to Veterans With Serious Mental Illness

PI: Alex Young, M.D.

VA Health Services Research and Development Service (IIR 09-083)

9/1/10-11/30/13 (\$924,466)

Role: Co-investigator

The goal of this project is to develop and evaluate an internet-based system that helps individuals with serious mental illness improve their diet and exercise and lose weight.

Randomized Trial of a Smoking Cessation Program for Persons with SMI

PI: Lisa Dixon, M.D., M.P.H.

VA Clinical Services Research and Development Service (1101CX00135-01A1)

10/1/09-9/30/13 (\$590,250)

Role: Co-investigator

This is a randomized trial of a psychosocial and behavioral smoking cessation program for persons with SMI.

Recovery After Initial Schizophrenia Episode (RAISE)

Co-PIs: Susan Essock, Ph.D., Lisa B. Dixon, M.D., M.P.H.

National Institute of Mental Health (contract)

7/11/09-12/31/13 (\$852,612)

Role: Co-Investigator

This proposal offers an unprecedented opportunity to fundamentally and favorably alter the trajectory and outcome of schizophrenia and related psychotic disorders through a multi-element, team-oriented and evidence-based intervention in the first episode of illness.

How Does a Psychiatric Comorbidity (Schizophrenia) Affect the Management of Diabetes?

PI: Karen Lutfey, Ph.D.

National Institute of Mental Health (R01 MH081824)

06/05/09-02/28/13 (\$2,003,916)

Role: Consultant

This study uses a factorial design to estimate of the effects of different types of patient, provider and health care system effects on primary care providers' decisions around managing diabetes for hypothetical patients with schizophrenia (with and without bizarre affect), depression, and eczema.

Enhancing Recovery of People With Schizophrenia

PI: Robert W. Buchanan, M.D.

National Institute of Mental Health (R24 MH082755)

8/11/08-4/30/13 (\$331,553 (annual))

Role: Co-Investigator

This is a Research Infrastructure Services Program grant to create a practice research network intended to facilitate the conduct of research throughout the state of Maryland.

A Patient-Centered Approach to Improve Screening for Side Effects of SGAs

PI: Julie Kreyenbuhl, Pharm.D., Ph.D.

VA Health Services Research and Development Service (IIR 07-256-1)

7/1/08-6/31/12 (\$900,000)

Adherence to guidelines for regular screening for the metabolic side effects of second-generation antipsychotic (SGA) medications is inadequate. The primary objectives of this randomized, controlled study are to determine whether exposure to a patient-centered computerized tool, compared to enhanced treatment as usual, increases rates of screening for the metabolic side effects of SGAs, enhances patterns of patient-clinician communication about screening, influences patients' preferences for obtaining health information and participating in decision-making about screening, and influences patients' perceptions of their psychiatrists' participatory decision-making styles around screening.

## **Publications**

### **Peer-Reviewed Journal Articles**

1. **Kreyenbuhl J**, Atwood CH. Are we teaching the right things in general chemistry? *J Chem Education* 1991; 68(11): 914-918.
2. **Kreyenbuhl J**, Zuckerman I. A survey to assess the practice characteristics and continuing education needs of long-term care pharmacists in Maryland. *Consultant Pharmacist* 1998; 4: 389-98.
3. McMahon RP, **Kreyenbuhl J**, Kirkpatrick B, Kelly DL, Love RC, Conley RR. Novel factor-based symptom scores in treatment-resistant schizophrenia: Implications for clinical trials. *Neuropsychopharmacology* 2002; 26(4):537-45.
4. Buchanan RW, **Kreyenbuhl J**, Zito JM, Lehman AF. The Schizophrenia PORT Pharmacological Treatment Recommendations: The relationship of the use of adjunctive pharmacological agents to symptoms and functional outcome. *Am J Psychiatry* 2002 Jun; 159(6): 1035-43.

5. Buchanan RW, **Kreyenbuhl J**, Zito JM, Lehman AF. The Schizophrenia PORT Pharmacological Treatment Recommendations: Conformance and implications for symptoms and functional outcome. *Schizophrenia Bulletin* 2002; 28(1): 63-73.
6. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, **Kreyenbuhl J**, Revicki D, Buchanan RW. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. *British Medical Journal* 2002; 325:243-245.
7. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, **Kreyenbuhl J**, Revicki D, Buchanan RW. An assessment of the independent effect of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenia patients. *Archives of General Psychiatry* 2002; 59: 1021-1026.
8. **Kreyenbuhl J**, Conley RR, Kelly DL. Circumstances of suicide among patients with schizophrenia. *Schizophrenia Research* 2002; 58:253-261.
9. Dickerson FB, McNary SW, Brown CH, **Kreyenbuhl J**, Goldberg RW, Dixon LB. Somatic healthcare utilization among adults with serious mental illness who are receiving community psychiatric services. *Medical Care* 2003; 41(4): 560-70.
10. **Kreyenbuhl J**, Zito JM, Buchanan RW, Soeken KL, Lehman AF. Racial disparity in the pharmacologic management of schizophrenia. *Schizophrenia Bulletin* 2003; 29(2): 183-193.
11. Kelly DL, **Kreyenbuhl J**, Love RC, Duong Q, Conley RR. Six-month review of weight and metabolic parameters in patients on clozapine, risperidone, olanzapine and quetiapine. *Journal of Clinical Psychiatry* 2003; 64:1133-4.
12. Lehman AF, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden L, **Kreyenbuhl J**. Evidence-based treatment for schizophrenia. *Psychiatr Clin North Am* 2003; 26(4): 939-54.
13. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, **Kreyenbuhl J**; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. *Am J Psychiatry* 2004;161(2 Suppl):1-56.
14. Lehman AF, **Kreyenbuhl J**, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, Sandson N. The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003. *Schizophrenia Bulletin* 2004; 30(2):193-217.
15. Sokal J, Messias E, Dickerson FB, **Kreyenbuhl J**, Brown CH, Goldberg RW, Dixon LB. Co-morbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. *Journal of Nervous and Mental Disease* 2004; 192(6): 421-427.

16. Lucksted A, McGuire C, Postrado L, **Kreyenbuhl J**, Dixon LB. Specifying cigarette smoking and quitting among people with serious mental illness. *The American Journal on Addictions/ American Academy of Psychiatrists in Alcoholism and Addictions* 2004; 13 (2):128-138.
17. Dixon L, **Kreyenbuhl J**, Dickerson F, Donner T, Brown C, Wohlheiter K, Postrado L, Goldberg R, Messias E, Fang L. A comparison of Type 2 diabetes outcomes among individuals with and without severe mental illnesses. *Psychiatric Services* 2004; 55: 892-900.
18. Dickerson FB, Brown CH, **Kreyenbuhl J**, Goldberg RW, Fang L, Dixon LB. Sexual and reproductive behaviors among persons with serious mental illness. *Psychiatric Services* 2004 55: 1299-1301.
19. Himelhoch S, Lehman AF, **Kreyenbuhl J**, Daumit G, Brown C, Dixon L. Prevalence of COPD among those with serious mental illness. *American Journal of Psychiatry* 2004; 161(12):2317-9.
20. Dickerson FB, Goldberg RW, Brown CH, **Kreyenbuhl JA**, Wohlheiter K, Fang L, Medoff D, Dixon LB. Diabetes knowledge among persons with serious mental illness and type 2 diabetes. *Psychosomatics* 2005; 46(5):418-24.
21. Daumit GL, Goldberg RW, Anthony C, Dickerson F, Brown CH, **Kreyenbuhl J**, Wohlheiter K, Dixon LB. Physical activity patterns in adults with severe mental illness. *Journal of Nervous and Mental Disease* 2005; 193: 641-646.
22. Goldberg RW, Himelhoch S, **Kreyenbuhl J**, Dickerson FB, Hackman A, Fang L, Brown CH, Wohlheiter KA, Dixon LB. Predictors of HIV and hepatitis testing and related service utilization among individuals with serious mental illness. *Psychosomatics* 2005; 46(6): 573-577.
23. Dickerson FB, Brown CH, **Kreyenbuhl JA**, Fang L, Goldberg RW, Wohlheiter K, Dixon LB. Obesity among individuals with serious mental illness. *Acta Psychiatr Scand* 2006; 113: 306-313.
24. Hackman AL, Goldberg RW, Brown CH, Fang L, Dickerson FB, Wohlheiter K, Medoff DR, **Kreyenbuhl JA**, Dixon L. The use of emergency department services for somatic reasons by people with serious mental illness. *Psychiatric Services* 2006; 57:563-566.
25. **Kreyenbuhl J**, Dickerson FB, Medoff DR, Brown CH, Goldberg RW, Fang L, Wohlheiter K, Mittal LP, Dixon LB. Extent and management of cardiovascular risk factors in patients with Type 2 diabetes and serious mental illness. *Journal of Nervous and Mental Disease* 2006; 194 (6): 404-410.
26. **Kreyenbuhl J**, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Long-term combination antipsychotic treatment in VA patients with schizophrenia. *Schizophrenia Research* 2006 May; 84(1):90-99.

27. Kelly DL, Dixon L, **Kreyenbuhl J**, Medoff D, Lehman AF, Love RC, Brown C, Conley RR. Clozapine utilization and outcomes by race in a public mental health system: 1994-2000. *Journal of Clinical Psychiatry* 2006; 67(9):1404-1411.
28. Kelly DL, **Kreyenbuhl J**, Dixon L, Love RC, Medoff D, Conley RR. Clozapine underutilization and discontinuation in African-Americans due to leucopenia. *Schizophrenia Bulletin* 2007; 33(5):1221-4.
29. **Kreyenbuhl J**, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Antipsychotic polypharmacy in the VA Health System: Patient characteristics and treatment patterns. *Psychiatric Services* 2007; 58(4): 489-495.
30. Goldberg RW, **Kreyenbuhl J**, Dickerson FB, Medoff D, Wohlheiter K, Fang L, Dixon L. Quality of diabetes care among adults with serious mental illness. *Psychiatric Services* 2007; 58 (4): 536-543.
31. Kelly DL, **Kreyenbuhl J**, Buchanan RW, Malhotra AK. Why Not Clozapine? *Clinical Schizophrenia & Related Psychoses* 2007; 1 (1): 92-95.
32. Dixon L, Medoff D, Wohlheiter K, DiClemente C, Goldberg R, **Kreyenbuhl J**, Adams C, Mfalila C, Lucksted A, Davin C. Correlates of severity of smoking among persons with SMI. *American Journal on Addictions* 2007; 16 (2): 101-110.
33. **Kreyenbuhl J**, Marcus SC, West JC, Wilk J, Olfson M. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. *Psychiatric Services* 2007; 58(7): 983-990.
34. Hackman A, Brown C, Yang Y, Goldberg R, **Kreyenbuhl J**, Lucksted A, Wohlheiter K, Dixon L. Consumer satisfaction with inpatient psychiatric treatment among persons with severe mental illness. *Community Mental Health Journal* 2007; 43 (6):551-64.
35. Dickerson F, Brown CH, Fang LJ, Goldberg RW, **Kreyenbuhl J**, Wohlheiter K, Dixon L. Quality of life in individuals with serious mental illness and Type 2 diabetes. *Psychosomatics* 2008; 49:109-114.
36. **Kreyenbuhl J**, Medoff DR, Seliger SL, Dixon LB. Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes. *Schizophrenia Research* 2008; 101: 256-265.
37. Goldberg R, Hackman A, Medoff D, Brown C, Fang L, Dickerson F, **Kreyenbuhl J**, Dixon L. Physical wellness and employment status among adults with serious mental illness. *Community Mental Health Journal* 2008; 44: 245-251.
38. Himelhoch S, Leith J, Goldberg R, **Kreyenbuhl J**, Medoff D, Dixon L. Care and management of cardiovascular risk factors among individuals with schizophrenia and Type 2 diabetes who smoke. *General Hospital Psychiatry* 2009 Jan-Feb; 31(1):30-2.

39. Dixon L, Goldberg R, Iannone V, Lucksted A, Brown C, **Kreyenbuhl J**, Fang L, Potts W. Use of a critical time intervention to promote continuity of care after psychiatric inpatient hospitalization. *Psychiatric Services* 2009 Apr; 60(4):451-8.
40. **Kreyenbuhl J**, Nossel IR, Dixon LB. Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: A review of the literature. *Schizophrenia Bulletin* 2009; 35 (4):696-703.
41. Dixon L, Medoff D, Goldberg R, Lucksted A, **Kreyenbuhl J**, DiClemente C, Potts W, Leith J, Brown C, Adams C, Afful J. Is implementation of the 5 A's of smoking cessation at community mental health centers effective for reduction of smoking by patients with serious mental illness? *The American Journal on Addictions* 2009; 18:386–392.
42. Dickerson FB, **Kreyenbuhl J**, Goldberg RW, Fang L, Medoff D, Brown CH, Dixon L. A 5-year follow-up of diabetes knowledge in persons with serious mental illness and type 2 diabetes. *Journal of Clinical Psychiatry* 2009; Jul;70(7):1057-8.
43. **Kreyenbuhl J**, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009. *Schizophr Bull* 2010 Jan; 36(1):94-103.
44. Buchanan RW, **Kreyenbuhl J**, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. *Schizophr Bull* 2010 Jan; 36(1):71-93.
45. Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, **Kreyenbuhl J**. The 2009 Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements. *Schizophr Bull* 2010 Jan; 36(1):48-70.
46. **Kreyenbuhl J**, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valenstein M. Does adherence to medications for Type 2 diabetes differ between individuals with versus without schizophrenia? *Schizophrenia Bulletin* 2010; 36(2): 428-435.
47. Brown C, Leith J, Dickerson F, Medoff D, **Kreyenbuhl J**, Fang L, Goldberg R, Potts W, Dixon L. Predictors of mortality in patients with serious mental illness and co-occurring type 2 diabetes. *Psychiatry Research* 2010; 177(1-2):250-4.
48. Nossel I, Calmes C, Brown C, **Kreyenbuhl J**, Goldberg R, Fang L, Dixon L. Patterns of emergency room use for medical conditions among those with serious mental illness. *Psychiatric Services* 2010; 61(12):1251-4.
49. **Kreyenbuhl J**, Leith J, Medoff DR, Fang L, Dickerson FB, Brown C, Goldberg RW, Potts W, Dixon LB. A comparison of adherence to hypoglycemic medications between type 2 diabetes patients with and without serious mental illness. *Psychiatry Research* 2011; 188: 109-114.

50. Xiang YT, Wang CY, Ungvari GS, **Kreyenbuhl JA**, Chiu H, Lai K, Edwin Ho Ming Lee, BO QJ, Dixon L. Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment in schizophrenia. *Pharmacopsychiatry* 2011; 44(4):135-41.
51. Dickerson F, Wohlheiter K, Medoff D, Fang L, **Kreyenbuhl J**, Goldberg R, Brown C, Dixon L. Predictors of quality of life in Type 2 diabetes patients with schizophrenia, major mood disorder, and without mental illness. *Quality of Life Research* 2011; 20(9); 1419-1425.
52. **Kreyenbuhl J**, Slade EP, Medoff DR, Brown CH, Ehrenreich B, Afful J, Dixon LB. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. *Schizophrenia Research* 2011; 131(1-3):127-32.
53. Brown CH, Medoff D, Dickerson FB, **Kreyenbuhl JA**, Goldberg RW, Fang L, Dixon L. Glucose control over time among type 2 diabetes patients with and without serious mental illness. *Journal of Nervous and Mental Disease* 2011;199 (11): 899-902.
54. Xiang YT, Wang CY, Si TM, Lee EH, He YL, Ungvari GS, Chiu HF, Shinfuku N, Yang SY, Chong MY, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Dixon LB, **Kreyenbuhl JA**, Tan CH. Clozapine use in schizophrenia: findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009. *Aust N Z J Psychiatry* 2011; 45(11):968-75.
55. Xiang YT, Dickerson F, **Kreyenbuhl J**, Ungvari GS, Wang CY, Si TM, Lee EH, He YL, Chiu HF, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N. Adjunctive mood stabilizer an benzodiazepine use in older asian patients with schizophrenia, 2001-2009. *Pharmacopsychiatry*. 2012 Jan 30. [Epub ahead of print]
56. Xiang YT, Dickerson F, **Kreyenbuhl J**, Ungvari GS, Wang CY, Si TM, Lee EH, He YL, Chiu HF, Lai KY, Shinfuku N, Yang SY, Chong MY, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Tan CH. Prescribing patterns of low doses of antipsychotic medications in older Asian patients with schizophrenia, 2001-2009. *Int Psychogeriatr*. 2012 Feb 3:1-7.
57. Himelhoch S, Slade E, **Kreyenbuhl J**, Medoff D, Brown C, Dixon L. Antidepressant prescribing patterns among VA patients with schizophrenia. *Schizophr Res*. 2012 Apr; 136(1-3):32-5.
58. Xiang YT, Dickerson F, **Kreyenbuhl J**, Ungvari GS, Wang CY, Si TM, Lee EH, Chiu HF, Lai KY, He YL, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N. Common use of anticholinergic medications in older patients with schizophrenia: findings of the Research on Asian Psychotropic Prescription Pattern (REAP) study, 2001-2009. *Int J Geriatr Psychiatry* 2012; May 7. doi: 10.1002/gps.3827. [Epub ahead of print]
59. Xiang YT, **Kreyenbuhl J**, Dickerson FB, Ungvari GS, Wang CY, Si TM, Lee EH, Chiu HF, Lai KY, He YL, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong MK,

Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N. Antipsychotic treatment in older schizophrenia patients with extrapyramidal side effects in Asia (2001 - 2009). *Int J Clin Pharmacol Ther* 2012; May 7. [Epub ahead of print]

60. Aakre JM, Medoff DR, Dixon LB, **Kreyenbuhl JA**. Beliefs about antipsychotic versus hypoglycemic medications among individuals with serious mental illness and type 2 diabetes. *Patient Prefer Adherence* 2012; 6:389-94.
61. West JC, Rae DS, Mojtabei R, Rubio-Stipec M, **Kreyenbuhl JA**, Alter CL, Crystal S. Clinically unintended medication switches and inability to prescribe preferred medications under Medicare Part D. *Journal of Psychopharmacology* 2012; Jun;26(6):784-93.
62. Duffy FF, West JC, Fochtmann LJ, Dixon L, **Kreyenbuhl J**, Mościcki EK, Plovnick R, Kunkle R. Performance in practice: Physician practice assessment tool for the care of adults with schizophrenia. *FOCUS: The Journal of Lifelong Learning in Psychiatry* 2012; 10:157-171.
63. Xiang YT, **Kreyenbuhl J**, Dickerson FB, Ungvari GS, Wang CY, Si TM, Lee EH, He YL, Chiu HF, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N. Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001-2009). *Aust N Z J Psychiatry*. 2012 Jul 11. [Epub ahead of print]

#### **Non-peer-reviewed journal articles**

1. **Kreyenbuhl J**. Challenges for the 90's: Misattribution of Symptoms in Older Patients. *The Older Patient* 1996; 1(2): 2-7.

#### **Books**

1. **Kreyenbuhl J**, Zito JM, Buchanan RW. Schizophrenia Patient Outcomes Research Team Pharmacologic Treatment Recommendations and Quick Reference Guide. (1996)

#### **Abstracts and/or Proceedings**

1. McMahon RP, **Kreyenbuhl J**, Kirkpatrick B, Kelly DL, Conley RR. New factor structure for symptom clusters in treatment-resistant schizophrenia using the Brief Psychiatric Rating Scale. *Schizophrenia Research* 2001; 49 (suppl.):18.
2. Guinjoan SM, **Kreyenbuhl J**, Kelly DL, Conley RR. Circumstances of suicide among individuals with schizophrenia. *Schizophrenia Research* 2001; 49 (suppl.): 32.
3. Conley RR, McMahon RP, **Kreyenbuhl J**, Kirkpatrick B, Love RC, Kelly DL. Response to clozapine in treatment-resistant schizophrenia: A new factor analysis. *Schizophrenia Research* 2001; 49 (suppl.): 222.
4. DaSilva R, Kelly DL, Love RC, McMahon RP, Yu Y, **Kreyenbuhl J**, Conley RR. Utilization and outcomes of quetiapine in the Maryland mental health system. *Schizophrenia Research* 2001; 49 (suppl.): 270.

5. **Kreyenbuhl J**, Kelly DL, Love RC, Conley RR. An evaluation of clozapine discontinuation in a public mental health system. *Schizophrenia Research* 2001; 49 (suppl.): 273.
6. Love RC, Kelly DL, **Kreyenbuhl J**, Conley RR. The use of second-generation antipsychotics in the public sector: Switching patterns and combined antipsychotic treatment. *Schizophrenia Research* 2001; 49 (suppl.): 274.
7. **Kreyenbuhl J**, Dixon LB, Dickerson F, Goldberg R, Brown CH. Antipsychotic medications and diabetes outcomes in the seriously mentally ill. *Schizophrenia Research* 2003; 60 (1) (suppl.): 337.
8. Dixon L, Lehman AF, Donner T, **Kreyenbuhl J**, Bellack AS, Delahanty J, Wohlheiter K, Postrado L. A comparison of patients with Type 2 diabetes and schizophrenia, major affective disorder, and no mental illness. *Schizophrenia Research* 2003; 60 (1) (suppl.): 335.
9. Wohlheiter KA, Delahanty J, Dixon L, **Kreyenbuhl J**, Dickerson F. The relationship of diet and exercise habits to hemoglobin A1C and body mass index in persons with Type 2 diabetes and a severe mental illness. *Schizophrenia Research* 2003; 60 (1) (suppl.): 349.
10. **Kreyenbuhl J**, Valenstein M, McCarthy JM, Ganoczy D, Blow FC. Patterns of combination antipsychotic treatment in with veterans with schizophrenia. *Schizophrenia Bulletin* 2005; 31 (2): 544.
11. Medoff DR, **Kreyenbuhl J**, Dickerson F, Brown C, Wohlheiter K, Goldberg R, Dixon L. Predictors of hemoglobin A1C levels in persons with diabetes and serious mental illness. *Schizophrenia Bulletin* 2005; 31 (2): 546.
12. Buchanan RW, **Kreyenbuhl J**, Kelly D, Noel J, Fischer B, Boggs D, Aquino P, Fang B, Peterson E, Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations. *Schizophrenia Bulletin* 2009; 35 (Supplement 1): 129.
13. Dixon LB, Dickerson F, Bellack A, Bennett M, Calmes C, Dickinson D, Goldberg R, Lehman A, Pasillas R, Peer J, Tenhula W, **Kreyenbuhl J**. The 2009 Schizophrenia PORT Psychosocial Treatment Recommendations. *Schizophrenia Bulletin* 2009; 35 (Supplement 1): 129.
14. Brown CH, Leith J, Dickerson FB, Medoff MR, Fang L, **Kreyenbuhl J**, Goldberg RW, Potts W, Dixon LB. Predictors of mortality in patients with serious mental illness and co-morbid diabetes. *Schizophrenia Bulletin* 2009; 35 (Supplement 1): 35.
15. **Kreyenbuhl J**, Buchanan R, Kelly D, Noel J, Boggs D, Fischer B, Himelhoch S, Fang B, Peterson E, Aquino P, Keller W. The 2009 schizophrenia patient outcomes research team (PORT) psychopharmacological treatment recommendations. *International Clinical Psychopharmacology* 2011; 26:e54-e55. doi: 10.1097/01.yic.0000405726.61759.a4.

### **Other Brief Communications**

1. **Kreyenbuhl J**, Valenstein M, McCarthy JF. Polypharmacy and adverse drug reactions: in reply. *Psychiatric Services* 2007; 58(7):1011-12.
2. **Kreyenbuhl J**, Olfson M, Marcus SC. Adding or switching antipsychotic medications: in reply. *Psychiatric Services* 2007; 58(10):1375-6.

### **Major Invited Speeches**

Invited Speaker, Grand Rounds, Springfield Hospital Center: *“Ethnic Considerations in the Psychopharmacologic Treatment of Schizophrenia,”* Sykesville, Maryland, December, 2000.

Invited Speaker, Grand Rounds, Crownsville State Hospital: *“Ethnic Considerations in the Psychopharmacologic Treatment of Schizophrenia,”* Crownsville, Maryland, December, 2000.

Invited Speaker, Temple University Department of Continuing Medical Education Conference: *Atypical Antipsychotic Medications: A Review of Metabolic, Clinical, and Legal Concerns: “Understanding Type 2 Diabetes Outcomes among Individuals with Severe Mental Illnesses,”* Philadelphia, Pennsylvania, October, 2004.

Invited Speaker, Dartmouth Psychiatric Research Center: *“Shared Decision-Making for Medication Treatments in Individuals with Severe Mental Illness: A Research Agenda,”* Hanover, New Hampshire, January, 2006.

Invited Panel Speaker, 47<sup>th</sup> Annual New Clinical Drug Evaluation Unit Meeting: *“Use of Medications to Reduce Cardiovascular Risk Among Individuals with Psychotic Disorders and Type 2 Diabetes,”* Boca Raton, Florida, June, 2007.

Invited Speaker, 2007 Government Supported Benefits Summit Meeting: *“Quality of Diabetes Care for Individuals with Serious Mental Illnesses,”* Park City, Utah, September, 2007.

Invited Speaker, Representatives of the Maryland Mental Hygiene Administration and the Core Service Agencies of the Maryland Public Mental Health System: *“Use of Medications to Reduce Cardiovascular Risk among Individuals with Psychotic Disorders and Type 2 Diabetes,”* Baltimore, Maryland, December, 2007.

Invited Speaker, A Workshop of the Institute of Medicine Roundtable on Evidence-Based Medicine, Best Practices in Health Care: Matching Practice with Opportunity, *“Use Case: Schizophrenia”*, Washington, D.C., September, 2008.

Invited Speaker, University of Maryland School of Medicine, Department of Psychiatry Grand Rounds: *“The 2009 Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations: Overview and Update Process,”* Baltimore, Maryland, March 2009.

Invited Speaker, Grand Rounds, Springfield Hospital Center: *“The 2009 Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations: Overview and Update Process,”* Sykesville, Maryland, April 2009.

Invited Speaker, VA Maryland Health Care System Research Day, Baltimore VA Medical Center. *“The Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations: 2009 Update,”* Baltimore, Maryland, May 2009.

Invited Speaker, National Institute of Mental Health-sponsored conference, Closing the Gaps: Reducing Disparities in Mental Health Treatment Through Engagement, *“Overview of Engagement in Mental Health Treatment and Evidence-Based Interventions for Enhancing Engagement in Individuals with Serious Mental Illness”*, Bethesda, Maryland, September 2011.

Invited Speaker, VA Health Services Research and Development (HSR&D) Service Cyberseminar, VIREC Clinical Informatics Seminar, *“A Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Second-Generation Antipsychotic Medication”*, October 2012.

### **Proffered Communications**

1. **Kreyenbuhl J**, Zuckerman I. (May 1996). Drug Therapy in the Prevention of Non-Steroidal Anti-Inflammatory Drug Induced Gastrointestinal Events. Poster presented at Graduate Student Research Day, University of Maryland, Baltimore.
2. **Kreyenbuhl J**, Zuckerman I. (April 1997). Patterns of Non-Steroidal Anti-Inflammatory Drug Use in Elderly Maryland Medicaid Recipients. Poster presented at the American Pharmacists Association Annual Meeting, Los Angeles, CA.
3. Zuckerman I, **Kreyenbuhl J**, Gilner MP, Walker L (April 1997). Prevalence of Potentially Inappropriate Drug Use in the Elderly Maryland Medicaid Population. Poster presented at the American Pharmacists Association Annual Meeting, Los Angeles, CA.
4. **Kreyenbuhl J**, Zuckerman I. (May 1997). Patterns of Non-Steroidal Anti-Inflammatory Drug Use in Elderly Maryland Medicaid Recipients. Poster presented at the Maryland Public Health Association Annual Meeting, Baltimore, MD.
5. **Kreyenbuhl J**, Zuckerman I. (May 1997). Patterns of Non-Steroidal Anti-Inflammatory Drug (NSAID) Use in Elderly Maryland Medicaid Recipients. Paper presented at Graduate Student Research Day, University of Maryland, Baltimore.
6. McNally DL, **Kreyenbuhl J**, Zuckerman IH. (April 1998). Patterns of Asthma Drug Use in a Medicaid Pediatric Population: A Retrospective DUR Analysis. Poster presented at the American Pharmacists Association Annual Meeting, Miami, FL.
7. McNally DL, **Kreyenbuhl J**, Zuckerman IH. (May 1998). Patterns of Asthma Drug Use in a Medicaid Pediatric Population: A Retrospective DUR Analysis. Poster Presented at the Maryland Public Health Association Annual Meeting, Baltimore, MD.
8. **Kreyenbuhl J**, Zito JM, Buchanan RW, Lehman AF. (May 1998). Pharmacoepidemiology of Schizophrenia: Findings from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Paper presented at Graduate Student Research Day, University of Maryland, Baltimore.
9. Duong QV, Kelly DL, **Kreyenbuhl J**, Love RC. (January 1999). An Investigation of the Clinical Correlates of Weight Gain in Patients Receiving Atypical Antipsychotics. Poster presented at the American Society of Health-System Pharmacists Annual Meeting, Orlando, FL.
10. **Kreyenbuhl J**, Zito JM, Buchanan RW, Lehman AF. (November 1999). Ethnic Disparity in Psychopharmacologic Treatments for Schizophrenia: Findings from the Schizophrenia PORT Client Survey. Paper Presented at the American Public Health Association Annual Meeting, Chicago, IL.
11. Conley RR, **Kreyenbuhl J**, Kelly DL. (February 2000). Circumstances of Suicide among Individuals with Schizophrenia. Poster presented at the Tenth Biennial Winter Workshop on Schizophrenia, Davos, Switzerland.
12. **Kreyenbuhl J**, Kelly DL, Conley RR. (May 2000). Circumstances of Suicide among Individuals with Schizophrenia. Poster presented at The American Psychiatric Association Annual Meeting, Chicago, IL.

13. **Kreyenbuhl J**, Kelly DL, Love RC, Conley RR. (May 2000). An Evaluation of Clozapine Discontinuation in a Public Mental Health System. Poster presented at the 40<sup>th</sup> Annual New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL.
14. **Kreyenbuhl J**, Marcus SC, West JC, Wang PS, Olfson M, Narrow W. (June 2002). Prescription of Combination Antipsychotic Treatments in a National Sample of Individuals with Schizophrenia-Spectrum Disorders. Poster presented at the 42<sup>nd</sup> Annual New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL.
15. Dixon LB, **Kreyenbuhl J**, Dickerson F, Goldberg R, Delahanty J. (June 2002). Quality and Outcomes of Diabetes Care for Individuals with Serious Mental Illnesses. Poster presented at the Academy for Health Services Research and Health Policy Annual Research Meeting, Washington, D.C.
16. Kelly DL, Dixon L, **Kreyenbuhl J**, Lehman AF, Love RC, Medoff D, Brown C, Conley RR. (June 2005). Clozapine Utilization and Outcomes by Race in a Public Mental Health System. Poster presented at the 45<sup>th</sup> Annual New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, FL.
17. **Kreyenbuhl J**, Dixon LB, McCarthy JF, Soliman S, Valenstein M. (February 2008). Adherence to Oral Hypoglycemic Medications among VA Patients with Schizophrenia and Type 2 Diabetes. Poster presented at the 2008 VA Health Services Research and Development Service Annual Meeting, Baltimore, MD.
18. **Kreyenbuhl J**, Buchanan RW, Dixon LB, Dickerson F. (March 2009). The 2009 Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations: Overview and Update Process. Paper presented at the 12<sup>th</sup> International Congress on Schizophrenia Research, San Diego, CA.
19. **Kreyenbuhl J**, Buchanan RW, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. (November 2009). The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Paper presented at the 15th Biennial Winter Workshop in Psychoses, Barcelona, Espana.
20. **Kreyenbuhl J**. (May 2011). A Patient-Centered Health Technology Intervention to Improve Screening for the Metabolic Side Effects of Second-Generation Antipsychotic Medications. Paper presented at the 2011 Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii.
21. **Kreyenbuhl J**, Dixon LB, Medoff DR, Rotondi A (August 2011). A Patient-Centered Approach to Improve Screening for Side Effects of Second-Generation Antipsychotics. Poster presented at the 5<sup>th</sup> Veterans Health Administration Mental Health Conference: Improving Veterans Mental Health Care for the 21<sup>st</sup> Century, Baltimore, Maryland.

### **Professional Licensure**

Maryland Pharmacist License #13157 (since 1993)

### **References**

Available upon request